Eventide Asset Management LLC Has $43.82 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Eventide Asset Management LLC lessened its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 48.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 383,454 shares of the company's stock after selling 355,699 shares during the period. Eventide Asset Management LLC owned about 0.31% of Vaxcyte worth $43,817,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Riverview Trust Co bought a new position in Vaxcyte during the third quarter worth $27,000. Blue Trust Inc. boosted its holdings in shares of Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after buying an additional 93 shares during the period. Fifth Third Bancorp acquired a new position in shares of Vaxcyte in the 2nd quarter valued at about $35,000. J.Safra Asset Management Corp grew its position in shares of Vaxcyte by 649.4% during the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock valued at $46,000 after buying an additional 526 shares during the last quarter. Finally, Meeder Asset Management Inc. raised its stake in Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock worth $80,000 after acquiring an additional 635 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Insider Activity

In related news, CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,479,005.02. This trade represents a 8.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Elvia Cowan sold 5,000 shares of the company's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total value of $538,350.00. Following the completion of the transaction, the senior vice president now directly owns 12,723 shares in the company, valued at $1,369,885.41. This represents a 28.21 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 102,464 shares of company stock worth $11,455,576. 3.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

PCVX has been the subject of several recent research reports. Mizuho upped their target price on Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a report on Tuesday, September 10th. BTIG Research increased their target price on Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Jefferies Financial Group boosted their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Leerink Partners increased their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a report on Tuesday, September 3rd. Finally, Bank of America lifted their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research report on Wednesday, September 4th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte currently has a consensus rating of "Buy" and a consensus price target of $147.50.

Vaxcyte Trading Up 0.4 %

PCVX stock traded up $0.36 during trading on Friday, hitting $94.34. The company had a trading volume of 809,063 shares, compared to its average volume of 906,580. The business has a 50 day moving average of $105.60 and a 200 day moving average of $90.35. The firm has a market capitalization of $11.76 billion, a price-to-earnings ratio of -20.51 and a beta of 1.01. Vaxcyte, Inc. has a fifty-two week low of $50.04 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same quarter last year, the business earned ($0.91) earnings per share. As a group, equities analysts predict that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.